Status:
COMPLETED
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
Lead Sponsor:
AGO Study Group
Conditions:
Ovarian Cancer
Cancer of the Fallopian Tube
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Although initially responsive to cytoreductive surgery and platinum- and/or taxane-based chemotherapy, a majority of patients with epithelial ovarian cancer, cancer of the fallopian tube or the perito...
Eligibility Criteria
Inclusion
- histologically confirmed epithelial ovarian cancer, cancer of the fallopian tube or peritoneum refractory to platinum- and taxane-based chemotherapy measurable or non-measurable disease written informed consent aged 18 years or older Karnofsky performance status \> 60%
Exclusion
- complete bowel obstruction symptomatic brain metastases known hypersensitivity to evaluated drugs inadequate kidney function inadequate hepatic function evidence of clinically active interstitial lung disease history of congestive heart failure \> NYHA 2
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00189358
Last Update
July 20 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Gynecology, Evangelisches Krankenhaus
Düsseldorf, Germany, 40217